Testosterone replacement therapy in hypogonadal men helps boost QoL
A total of 261 men with LOH and on-going treatment of 1,000 mg long-acting intramuscular testosterone undecanoate for at least 1 year were enrolled in the study and followed-up for 5 years. To establish the association between long-term TRT and health-related quality of life, researchers obtained the International Prostate Symptom Score (IPSS), the five-item International Index of Erectile Function (IIEF-5), and the Aging Males’ Symptoms (AMS) scale at enrollment and at subsequent follow-ups. Total testosterone level was also determined at baseline and at each visit. The proportion of patients reporting symptoms of joint and muscle pain was also collected.
Within the first 3 months, the mean IPSS significantly decreased from the baseline score of 10.35 to 9.5 (p=< 0.05) and constantly decreased, reaching 7.22 at the end of the trial period. Similarly, mean AMS of 54.27 at baseline also significantly decreased to 37.42 (p= 0.05) within the first 3 months of TRT and steadily dropped to 28.66 at the end of the study.
The mean IIEF-5 score and TT level had significantly increased throughout the study period while the baseline mean IIEF-5 score of 7.8 increased to 21.96 at the end of the trial. Baseline TT of 2.23 ng/mL reached up to 5.39 ng/mL after the study.
By the end of the trial period, there was a significant reduction in the percentage of patients with arthralgia and myalgia.
Late-onset hypogonadism is mainly characterized by symptoms of erectile dysfunction, low sexual drive, fatigue, depression and a serum TT of ⩽3.5 ng/mL (12 nmol/L). The study highlighted the effectiveness of long-term TRT in improving HRQoL and overall sense of well-being among men with LOH.